InvestSMART

Nyrada Inc (ASX:NYR)

ALERT: Price-sensitive ASX Announcement for NYR
Current share price for NYR : $0.550 -0.025 (-4.35%)+
Announcement
Release
15 Jul 2026 4:58PM
Price at Release
$0.575
Full Release
download
Summary
Nyrada Inc., a biotechnology company focused on developing therapies targeting TRPC ion channels, addressed an ASX price query following a notable increase in its share price and trading volume. The company, which has its lead candidate Xolatryp® in Phase IIa trials, confirmed that it is unaware of any undisclosed information that could explain the recent trading activity. Nyrada assured its compliance with ASX Listing Rules and stated that its responses were authorized by CEO James Bonnar.
Key Points
  • Nyrada Inc. is a clinical-stage biotechnology company.
  • The company focuses on small-molecule therapies targeting TRPC ion channels.
  • Lead candidate Xolatryp® has shown efficacy in various models and completed Phase I trials.
  • A significant increase in NYR's share price and trading volume was noted.
  • ASX inquired about unexplained recent trading activity.
  • Nyrada confirms no undisclosed information to explain the trading activity.
  • Nyrada affirms compliance with ASX Listing Rules, especially Rule 3.1.
  • The response to ASX was authorized by CEO James Bonnar.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.